Developing a cure for lung cancer represents the biggest challenge of the last decades in oncology. Our therapeutic possibilities are expanded, but the inoperable non small-cellular lung cancer patients’ chances of survival are inconspicuous (5 year survival – regardless to treatment – is around 14%). The rapid development of molecular genetics, the automatization of drug-synthesis put down the basis of targeted molecular tumor therapy. In our paper we would like to present two cases from our database, in which using 3rd line gefitinib as chemotherapeutic method we achieved important radiological and clinical regression. In the case of our patients, after using the traditional citostatic method, we applied the “new target point” gefitinib and obtained important radiological regression and quality of life improvement.